Trial · NCT01995487
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Target Lesion Failure (TLF) | 12 months | The primary endpoint of TLF at 12 months was defined as the composite of cardiac death, target vessel-related MI, or ischemia-driven TLR. |
| Secondary | Device Success | Determined at time of baseline procedure | Clinical: Acute secondary endpoint determined at time of baseline procedure |
| Secondary | TLF | 30 days, 6 months, and 1, 2, 3, 4 and 5 years | Clinical secondary endpoint to be evaluated at 30 days, 6 months, and 2, 3, 4 and 5 years, defined as the composite of cardiac death, target vessel-related MI, or ischemia-driven TLR |
| Secondary | Major Adverse Cardiac Events | 30 days, 6 months, and 1, 2, 3, 4 and 5 years | Clinical: MACE; the composite rate of cardiac death, any MI or ischemia-driven TLR |
| Secondary | Target Vessel Failure | 30 days, 6 months, and 1, 2, 3, 4 and 5 years | Clinical: TVF; the composite rate of death, target vessel related MI or ischemia-driven TVR |
| Secondary | All Cause Mortality | 30 days, 6 months, and 1, 2, 3, 4 and 5 years | Clinical: The number of patients who die from all causes |
| Secondary | Cardiac Death | 30 days, 6 months, and 1, 2, 3, 4 and 5 years | Clinical: The number of patients who die of cardiac-related causes |
| Secondary | Myocardial Infarction | 30 days, 6 months, and 1, 2, 3, 4 and 5 years | Clinical: The number of patients who suffer a myocardial infarction. |
| Secondary | Target Vessel Related MI | 30 days, 6 months, and 1, 2, 3, 4 and 5 years | Clinical: The number of patients who suffer a MI that is related to the target vessel of the procedure. |
| Secondary | Ischemia Driven TLR | 30 days, 6 months, and 1, 2, 3, 4 and 5 years | Clinical: |
| Secondary | Ischemia Driven TVR | 30 days, 6 months, and 1, 2, 3, 4 and 5 years | Clinical: |
| Secondary | Stent Thrombosis | 30 days, 6 months, and 1, 2, 3, 4 and 5 years | Clinical: ARC definite and probable |
| Secondary | Angiographic Sub-Study: In-stent and In-segment Late Loss | 13 months | Secondary Endpoint for angiographic in-stent and in-segment late loss |
| Secondary | IVUS Sub-Study: In-stent Percent Neointimal Hyperplasia | 13 months | IVUS: In-stent percent neointimal hyperplasia |
| Secondary | IVUS Sub-Study: Stent Mal-apposition | 13 months | IVUS Sub-Study: Stent mal-apposition |
| Secondary | Lesion Success | Determined at time of baseline procedure | Measures whether the lesion was successfully treated. |
| Secondary | Procedure Success | Determined at time of baseline procedure | Acute clinical endpoint: The success of the procedure as determined at time of baseline procedure |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01995487/registered